Evidence map›Paper›PMID 36229880›Full record

ArticleRadiation oncology (London, England)2022

Management after initial surgery of nonfunctioning pituitary adenoma: surveillance, radiotherapy or surgery?

Thomas Charleux, Véronique Vendrely, Aymeri Huchet, Renaud Trouette, Amandine Ferrière, Antoine Tabarin, Vincent Jecko, Hugues Loiseau, Charles Dupin

Open access · goldAbstract read
In one paragraph

Article in Radiation oncology (London, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. The Evolution of Pituitary Surgery in an Australian Health Care Framework.Journal of neurological surgery. Part B, Skull base · 2025
    Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Thomas CharleuxRadiotherapy Department, CHU Bordeaux, 33000, Bordeaux, France.
Véronique VendrelyRadiotherapy Department, CHU Bordeaux, 33000, Bordeaux, France.
Aymeri HuchetRadiotherapy Department, CHU Bordeaux, 33000, Bordeaux, France.
Renaud TrouetteRadiotherapy Department, CHU Bordeaux, 33000, Bordeaux, France.
Amandine FerrièreEndocrinology Department, CHU Bordeaux, 33000, Bordeaux, France.
Antoine TabarinEndocrinology Department, CHU Bordeaux, 33000, Bordeaux, France.
Vincent JeckoNeurosurgery Department, CHU Bordeaux, 33000, Bordeaux, France.
Hugues LoiseauNeurosurgery Department, CHU Bordeaux, 33000, Bordeaux, France.
Charles DupinRadiotherapy Department, CHU Bordeaux, 33000, Bordeaux, France. charles.dupin@chu-bordeaux.fr.
Centre Hospitalier Universitaire de Bordeaux · FRUniversité de Bordeaux · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe first line of treatment for nonfunctioning pituitary adenoma (NFPA) is surgery. Adjuvant radiotherapy or surveillance and new treatment (second surgical operation or salvage radiotherapy) in case of recurrence are options discussed at the multidisciplinary tumor board. The purpose of this study was to evaluate the therapeutic outcome for each option.

methodsThe records of 256 patients followed with NFPA between 2007 and 2018 were retrospectively reviewed. Mean age at initial surgery was 55 years [18-86]. Post-operative MRI found a residual tumor in 87% of patients. Mean follow-up was 12.1 years [0.8-42.7].

resultsAfter initial surgery, 40 patients had adjuvant radiotherapy. At 5, 10 and 15 years progression-free survival (PFS) was significantly different after surgery alone (77%, 58% and 40%) compared to surgery and adjuvant radiotherapy (84%, 78% and 78%) (HR = 0.24 [0-0.53] p < 0.0005). Overall, after first, second or third surgical operation, 69 patients had adjuvant radiotherapy and 41 salvage radiotherapy. Five-year PFS was similar for adjuvant (90%) and salvage radiotherapy (97%) (p = 0.62). After a second surgical operation, 62% and 71% of patients were irradiated after 2 and 5 years respectively. The risk of corticotropic and thyrotropic deficiency rates were 38% and 59% after second or third surgical operation and 40% and 73% after radiotherapy. Brain tumors occurred in 4 patients: 1 meningioma present at initial surgery, and after radiotherapy, 1 neurinoma which appeared at 5 years, 1 glioblastoma at 13 years and 1 meningioma at 20 years.

conclusionAmong patients treated by surgery for NFPA, a "wait-and-see" attitude should be an option since adjuvant radiotherapy is not superior to salvage radiotherapy. However, in case of recurrence or progression, the authors recommended delivery of salvage radiotherapy to avoid a second surgical operation.

Indexed as

AdenomaMeningeal NeoplasmsMeningiomaPituitary NeoplasmsFollow-Up StudiesHumansMiddle AgedNeoplasm Recurrence, LocalRadiotherapy, AdjuvantRetrospective StudiesTreatment OutcomeNon-functioning pituitary adenomaRadiotherapySurgeryWait and see

Identifiers

PMID36229880
PMCPMC9559766
OpenAlexW4304891889

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.